Sutro Biopharma Inc (STRO) extends its cash runway and strengthens partnerships while navigating workforce cuts and ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -SOUTH SAN FRANCISCO, Calif., March 15, ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

Oppenheimer analyst Jay Olson downgraded Sutro Biopharma (STRO) to Perform from Outperform after the company reported Q4 results and announced ...

Sutro Biopharma (STRO) stock drops 14% after deprioritizing ADC program; analysts from Bank of America and Citizens slash ratings in reaction. Read more here.

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...